Cambiar Investors Has Decreased Acorda Therapeutics (ACOR) Stake; Brigade Capital Management LP Lowered Its Oclaro (Put) (OCLR) Holding

February 20, 2018 - By Adrian Erickson

Cambiar Investors Llc decreased Acorda Therapeutics Inc (ACOR) stake by 62.52% reported in 2017Q3 SEC filing. Cambiar Investors Llc sold 538,512 shares as Acorda Therapeutics Inc (ACOR)’s stock declined 39.72%. The Cambiar Investors Llc holds 322,819 shares with $7.64M value, down from 861,331 last quarter. Acorda Therapeutics Inc now has $1.21B valuation. The stock increased 2.79% or $0.7 during the last trading session, reaching $25.8. About 645,771 shares traded. Acorda Therapeutics, Inc. (NASDAQ:ACOR) has declined 40.68% since February 20, 2017 and is downtrending. It has underperformed by 57.38% the S&P500.

Brigade Capital Management Lp decreased Oclaro Inc (Put) (OCLR) stake by 33.33% reported in 2017Q3 SEC filing. Brigade Capital Management Lp sold 500,000 shares as Oclaro Inc (Put) (OCLR)’s stock declined 22.87%. The Brigade Capital Management Lp holds 1.00M shares with $8.63 million value, down from 1.50M last quarter. Oclaro Inc (Put) now has $1.16 billion valuation. The stock increased 1.18% or $0.08 during the last trading session, reaching $6.87. About 2.38M shares traded. Oclaro, Inc. (NASDAQ:OCLR) has risen 92.74% since February 20, 2017 and is uptrending. It has outperformed by 76.04% the S&P500.

Brigade Capital Management Lp increased Tenet Healthcare Corp (NYSE:THC) stake by 303,475 shares to 1.35 million valued at $22.18M in 2017Q3. It also upped Rowan Companies Plc (NYSE:RDC) stake by 46,000 shares and now owns 271,000 shares. Spdr S&P 500 Etf Tr (Put) (SPY) was raised too.

Among 18 analysts covering Oclaro Inc (NASDAQ:OCLR), 13 have Buy rating, 1 Sell and 4 Hold. Therefore 72% are positive. Oclaro Inc had 51 analyst reports since August 18, 2015 according to SRatingsIntel. The rating was maintained by Piper Jaffray on Monday, September 11 with “Buy”. Needham downgraded Oclaro, Inc. (NASDAQ:OCLR) on Monday, December 18 to “Hold” rating. The firm has “Buy” rating given on Thursday, July 13 by Cowen & Co. The firm has “Buy” rating by Stifel Nicolaus given on Wednesday, August 23. The stock of Oclaro, Inc. (NASDAQ:OCLR) has “Buy” rating given on Thursday, September 7 by Jefferies. On Thursday, November 2 the stock rating was maintained by Northland Capital with “Buy”. Drexel Hamilton initiated Oclaro, Inc. (NASDAQ:OCLR) on Friday, April 8 with “Hold” rating. The stock has “Hold” rating by Jefferies on Friday, February 2. As per Monday, January 29, the company rating was maintained by Northland Capital. The rating was maintained by Stifel Nicolaus with “Buy” on Tuesday, September 6.

Investors sentiment decreased to 1.28 in Q3 2017. Its down 0.23, from 1.51 in 2017Q2. It is negative, as 43 investors sold OCLR shares while 60 reduced holdings. 39 funds opened positions while 93 raised stakes. 115.55 million shares or 1.25% more from 114.12 million shares in 2017Q2 were reported. Thrivent For Lutherans stated it has 0% in Oclaro, Inc. (NASDAQ:OCLR). New York State Teachers Retirement System reported 78,367 shares or 0% of all its holdings. Alps Advsr Inc stated it has 55,352 shares or 0% of all its holdings. Natixis owns 23,394 shares. Principal Grp Inc has 1.29 million shares. Nj State Employees Deferred Compensation Plan invested in 0.13% or 80,000 shares. Segall Bryant And Hamill Limited Liability Company accumulated 270,265 shares. Citadel reported 0.02% stake. Invesco Limited stated it has 0% of its portfolio in Oclaro, Inc. (NASDAQ:OCLR). 1.63M were reported by Geode Mngmt Ltd Limited Liability Company. Us Commercial Bank De invested in 0% or 5,235 shares. Nomura accumulated 150,000 shares. Bnp Paribas Arbitrage, a New York-based fund reported 105,211 shares. Creative Planning holds 34,594 shares or 0% of its portfolio. Manufacturers Life Insur The reported 0.01% of its portfolio in Oclaro, Inc. (NASDAQ:OCLR).

Among 14 analysts covering Acorda Therapeutics (NASDAQ:ACOR), 5 have Buy rating, 1 Sell and 8 Hold. Therefore 36% are positive. Acorda Therapeutics had 43 analyst reports since August 25, 2015 according to SRatingsIntel. H.C. Wainwright maintained it with “Buy” rating and $31.0 target in Wednesday, January 17 report. Janney Capital maintained the stock with “Hold” rating in Wednesday, January 31 report. The stock of Acorda Therapeutics, Inc. (NASDAQ:ACOR) has “Perform” rating given on Wednesday, January 31 by Oppenheimer. The stock has “Hold” rating by Leerink Swann on Tuesday, August 29. Cowen & Co maintained Acorda Therapeutics, Inc. (NASDAQ:ACOR) rating on Monday, June 5. Cowen & Co has “Buy” rating and $3500 target. The rating was upgraded by Goldman Sachs on Wednesday, February 15 to “Neutral”. On Tuesday, September 1 the stock rating was initiated by Aegis Capital with “Buy”. The firm has “Hold” rating by Cantor Fitzgerald given on Tuesday, August 29. The firm earned “Hold” rating on Tuesday, October 31 by Cantor Fitzgerald. The company was upgraded on Thursday, February 15 by Piper Jaffray.

Since August 29, 2017, it had 1 buy, and 3 sales for $12.92 million activity. Another trade for 250 shares valued at $6,350 was made by LAWRENCE DAVID on Monday, October 9. The insider Wasman Jane sold $952,319. $14.73 million worth of Acorda Therapeutics, Inc. (NASDAQ:ACOR) was bought by SCOPIA CAPITAL MANAGEMENT LP.

Investors sentiment decreased to 1.22 in Q3 2017. Its down 0.03, from 1.25 in 2017Q2. It dropped, as 19 investors sold ACOR shares while 39 reduced holdings. 22 funds opened positions while 49 raised stakes. 51.31 million shares or 4.56% more from 49.07 million shares in 2017Q2 were reported. Bnp Paribas Arbitrage Sa has 23,904 shares. State Of Alaska Department Of Revenue invested 0.01% in Acorda Therapeutics, Inc. (NASDAQ:ACOR). Meeder Asset Management Inc holds 0% of its portfolio in Acorda Therapeutics, Inc. (NASDAQ:ACOR) for 792 shares. Dimensional Fund Advsrs Ltd Partnership holds 0.03% or 2.66M shares in its portfolio. Citigroup reported 71,814 shares. Bluecrest Cap Mngmt stated it has 14,568 shares or 0.01% of all its holdings. Jpmorgan Chase holds 0% or 543,224 shares in its portfolio. 4.05 million were accumulated by Partner Fund Management Limited Partnership. Group Inc One Trading LP holds 0% in Acorda Therapeutics, Inc. (NASDAQ:ACOR) or 5,309 shares. Gotham Asset Limited Company reported 153,742 shares. Fmr Limited stated it has 0.02% of its portfolio in Acorda Therapeutics, Inc. (NASDAQ:ACOR). Ra Cap Ltd reported 1.92% of its portfolio in Acorda Therapeutics, Inc. (NASDAQ:ACOR). Great West Life Assurance Can invested in 0% or 62,860 shares. Jacobs Levy Equity Mgmt Incorporated reported 306,217 shares or 0.14% of all its holdings. Price T Rowe Assoc Md reported 215,220 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: